Video

Dr. O'Malley Discusses the Current Role of PARP Inhibitors in Ovarian Cancer

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the current role for PARP inhibitors for patients with ovarian cancer.

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the current role for PARP inhibitors for patients with ovarian cancer.

PARP inhibitors have a role in a couple of different patient populations, explains O’Malley. One of those populations is BRCA mutations, either germline or somatic. Olaparib (Lynparza) has indications in patients with a germline mutation who have had 3 or more prior lines of therapy, while rucaparib (Rubraca) is indicated for both somatic and germline tumors with more than 2 lines of prior therapy.

There are now 2 drugs that are approved in the platinum-sensitive maintenance setting. Those are olaparib and niraparib (Zejula). According to O’Malley, rucaparib has been submitted to the FDA but it is not known if it will receive approval.

In this population of patients, many of the trials are concentrated on BRCA mutations as well as homologous recombination deficiency status. Both current drugs are approved in all-comers no matter their somatic or germline status.

Related Videos
Roger Li, MD, of Moffitt Cancer Center
Michael Deininger, MD, PhD
Shubham Pant, MD, MBBS
Kedar Kirtane, MD
Mazyar Shadman, MD, MPH
Allison Winter, MD, Department of Hematology and Medical Oncology, Cleveland Clinic
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology